News
Fighting the Uphill War Against Illicit Drugs and Overdose Deaths: Detecting Emerging Designer Drugs and Opioid Analogs
The drugs flowing into the U.S. are changing more in their mix than in their amount, according to CFSRE’s NPS Discovery experts. “The nitazene analogs have replaced the fentanyl analogs,” Krotulski said, “but they are not replacing fentanyl itself. There is no indication that anything is replacing the amount of fentanyl across the country right now.”
CFSRE Secures New State-of-the-Art Facility
The Center for Forensic Science Research and Education (CFSRE) was established in Willow Grove, Penn. at the nonprofit Fredric Rieders Family Foundation in 2010. The CFSRE provides training, education and research that advances the capability, acceptance, and integrity of forensic science as it informs public health and public safety policy and missions.
Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients
Synthetic opioids, such as the fentanyl analogue and nitazene drug class, are among the fastest growing types of opioids being detected in patients in the emergency department (ED) with illicit opioid overdose (OD). However, clinical outcomes from OD of novel potent opioids (NPOs), specifically nitazenes, are unknown aside from small case series.
Delivering an Open-Access Drug Early Warning System for Novel Psychoactive Substances Case Study
The Center for Forensic Science Research and Education’s evidence-based approach to identifying emerging drugs delivers high impact data for real-time action with help from Waters analytical instrumentation and customer support services.
Dead Floridians are Testing Positive for this New Party Drug
10 Investigates started looking into N,N-Dimethylpentylone after we talked to forensic toxicologist Dr. Bruce Goldberger in November 2022.
Plasma Pharmacokinetics and Pharmacodynamic Effects of the 2-benzylbenzimidazole Synthetic Opioid
The aims of the present study were to investigate the pharmacokinetics of isotonitazene in rats, and relate pharmacokinetic parameters to pharmacodynamic effects.
Early-Career Forensic Toxicologists Take Home Top Awards for NIJ-Funded Research
Bench scientists and student researchers are often under-represented at forensic science conferences due to budgetary constraints. To encourage the participation of young researchers, the Society of Forensic Toxicologists (SOFT) supports three prestigious awards: the Young Scientist Meeting Award, the Master Level Educational Research Award, and the Doctorate Level Educational Research Award. This year, NIJ-funded researchers earned recognition for their exceptional work in each of the three categories....
Exclusive: $12M Center for Diagnostics Discovery Under Development in Horsham
Space that previously housed an insurance company's mail order pharmacy is being transformed into a home for fledgling entrepreneurs working on "cutting-edge" diagnostic products and processes to improve how and when diseases are detected.
The $12 million incubator project,called the Center for Diagnostics Discovery, is the brainchild of Eric Rieders , an owner and former CEO of NMS Labs, a Horsham-based bioanalytical toxicology and forensicsciences laboratory.
The Center for Diagnostics Discovery is being created in about 50,000 square feet of space last leased by Cigna in the 150,000-square-foot building that houses NMS Labs. The building at 206 Welsh Road is owned by the Rieders family, which founded NMS Labs.
CFSRE Forensic Toxicologist Sara Walton Receives 2022 SOFT Young Scientist Meeting Award
The Society of Forensic Toxicology (SOFT) Awards Committee selected CFSRE’s Forensic Toxicologist, Sara Walton, as this year’s Young Scientist Meeting Award (YSMA) recipient! This award recognizes young scientists performing outstanding forensic toxicology research. Help us in congratulating Sara for this prestigious award!
The title of her abstract was “Pharmacology and Toxicology of N-Pyrrolidino Etonitazene – A New Nitazene Synthetic Opioid Increasingly Observed in Forensic Cases”. This research was funded by the National Institute of Justice, Office of Justice Programs, U.S. Department of Justice (Award Number 2020-DQ-BX-0007, “Real-Time Sample-Mining and Data-Mining Approaches for the Discovery of Novel Psychoactive Substances (NPS)”). The opinions, findings, conclusions and/or recommendations expressed in this presentation are those of the author(s) and do not necessarily reflect those of the Department of Justice.
Emergent Synthetic Stimulant Replacing Drug Sold as Ecstasy, Molly
In 2020 and 2021, the Schedule I drug eutylone—typically sold as ecstasy, Molly or MDMA—was the most commonly encountered synthetic stimulant in forensic casework. While regulated in countries beside the U.S., including Canada, the UK, Sweden and Germany, eutylone is not controlled under the 1961, 1971 or 1988 United Nations Conventions. Stakeholders are seeking to change that.
